ClinicalTrials.gg
RecruitingNCT04947098CCPWUpdated Feb 17, 2026

Prevent Cancer- Greenville

An observational study in Cancer and High-Risk Cancer, sponsored by Prisma Health-Upstate. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Prisma Health-Upstate · Observational

From the registry’s dates

  • Started Nov 2018; still recruiting 8 years later.
Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Prevent Cancer-Greenville was created to provide individuals with the opportunity to have their risk of developing cancer studied. Some individuals may be at a higher risk due to their personal lifestyle, family history and/or exposures. If subjects are found to be at high risk for developing a disease, they will be sent to a healthcare provider for further care.

Read the detailed description

Participants' personal history, lifestyle behaviors and blood, urine, and cheek swab specimens will be used to detect changes or trends that might put them at risk for developing cancer. Some individuals may be at an above average risk of cancer due to lifestyle, family background, personal genetic makeup, or environmental exposures. This will be determined by a process called risk stratification. Risk stratification involves looking at all health-related aspects of a person, determining their individualized risk through screening, and educating them on measures to reduce potential for disease. Participants will complete a yearly health assessment which includes measurements for nutrition, activity, individual risk factors and body composition, including weight height and a special scale which measures fluid and fat.

02

Conditions studied

  • Cancer
  • High-Risk Cancer

Browse trials for

03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Prisma Health-Upstate is the lead sponsor of 76 studies on the registry; 7 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals 18 years or older

Eligibility criteria

Inclusion Criteria:

  • 18 years or older
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Assess changes in nutrition by nutrition questionnaire

    Nutrition will be assessed yearly by a questionnaire based on nutrition recommendations from the American Institute for Cancer Research and the U.S. Department of Health and Human Services.

    Time frame: Yearly follow up for 10 years

  2. Assess changes in physical activity by physical activity questionnaire

    Physical activity will be assessed yearly a questionnaire based on physical activity recommendations from the U.S. Department of Health and Human Services.

    Time frame: Yearly follow up for 10 years

  3. Assess changes in smoking habits

    Participants will be educated on healthy lifestyle habits and smoking habits will be assessed yearly.

    Time frame: Yearly follow up for 10 years

  4. Assess changes in alcohol use

    Participants will be educated on healthy lifestyle habits and alcohol use will be assessed yearly.

    Time frame: Yearly follow up for 10 years

  5. Assess hereditary risk through family history review

    Each participant's family history will be reviewed to make recommendations for screening or genetic testing based on National Comprehensive Cancer Network guidelines.

    Time frame: Yearly follow up for 10 years

  6. Assess lifetime breast cancer risk through the Tyrer-Cuzick version 8 breast risk evaluation tool

    Participants' breast cancer risk will be assessed using the Tyrer-Cuzick breast cancer risk model. Participants will be referred to appropriate clinics if lifetime risk is greater than 20 percent.

    Time frame: Yearly follow up for 10 years

  7. Assess 5- year breast cancer risk through the GAIL breast risk evaluation tool

    Participants' breast cancer risk will be assessed using the National Cancer Institute's GAIL model. Participants will be referred to appropriate clinics if GAIL 5 year risk is greater than 1.7 percent.

    Time frame: Yearly follow up for 10 years

  8. Early detection of malignancies through screening

    Participants will be educated on screening recommendations by the American Cancer Society. Malignancies will be recorded yearly if found by recommended screenings.

    Time frame: Yearly follow up for 10 years

  9. Assess changes in fat mass by SOZO measurements

    Body composition will be assessed yearly by measurements taken from the SOZO device which uses bioimpedance spectroscopy to measure fat mass.

    Time frame: Yearly follow up for 10 years

  10. Assess changes in muscle mass by SOZO measurements

    Body composition will be assessed yearly by measurements taken from the SOZO device which uses bioimpedance spectroscopy to measure muscle mass.

    Time frame: Yearly follow up for 10 years

Secondary outcomes

  1. Assess changes in quality of life by the 5-level EuroQol-5D version (EQ-5D-5L) questionnaire

    Quality of life will be assessed yearly by the EQ-5D-5L questionnaire. Participants' will self-report their health on a scale numbered 0-100. 100 means the best health you can imagine and 0 means the worst health you can imagine.

    Time frame: Yearly follow up for 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data sets will be available upon requests following institutional approval.

Supporting information: Study protocol, Informed consent form, Clinical study report

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04947098
Lead sponsor
Prisma Health-Upstate
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Nov 8, 2018
Primary completion
Nov 8, 2028 (estimated)
Completion
Nov 8, 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Patricia Wilson, MSN Ed. OCN ONNCG
Contact
ccpw@prismahealth.org
864-455-4897
Joe Stephenson, MD
principal investigator · Prisma Health-Upstate

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion